The action of neuroleptics in rats with altered catecholamine metabolism. II. The effects of chlorpromazine, haloperidol, and thioridazine on brain noradrenaline content elevated by previous administration of MAO inhibitors.
D000818:Animals; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects; D002540:Cerebral Cortex / Q000032:analysis; D002746:Chlorpromazine / Q000494:pharmacology*; D003342:Corpus Striatum / Q000032:analysis; D004347:Drug Interactions; D005260:Female; D006220:Haloperidol / Q000494:pharmacology*; D006624:Hippocampus / Q000032:analysis; D006801:Humans; D007031:Hypothalamus / Q000032:analysis; D008526:Medulla Oblongata / Q000032:analysis; D008636:Mesencephalon / Q000032:analysis; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009526:Nialamide / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism*; D010293:Pargyline / Q000494:pharmacology; D011149:Pons / Q000032:analysis; D051381:Rats; D013788:Thalamus / Q000032:analysis; D013881:Thioridazine / Q000494:pharmacology*; D013997:Time Factors
D008996:Monoamine Oxidase Inhibitors; D010293:Pargyline; D006220:Haloperidol; D013881:Thioridazine; D009526:Nialamide; D002746:Chlorpromazine; D009638:Norepinephrine